Antibody-drug conjugates (ADCs) have emerged as one of the fastest-growing oncology therapeutics – Antonio Passaro
I am delighted to share the our recent publication in JCO titled “Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies.”
Antibody-drug conjugates (ADCs) have emerged as one of the fastest-growing oncology therapeutics, offering a unique combination of the cytotoxic effect of conjugated payloads and the high specificity and selectivity of monoclonal antibodies targeted to cancer cell membrane antigens.
Numerous ADCs are currently under evaluation, both as monotherapy and in combination with other molecules such as chemotherapy agents or immune checkpoint inhibitors.
The optimal strategy for patient selection is evolving. In this manuscript, we provide a comprehensive discussion on various aspects of ADCs in lung cancer treatment, including structure-based drug design, mechanism of action, and concepts of resistance. The data are summarized based on specific target antigens, encompassing their biology, efficacy, and safety profiles, which can differ among ADCs due to variations in payload, pharmacokinetics, and pharmacodynamics properties.
By shedding light on the recent advances and implementing strategies in ADC-based therapy for lung cancer, this publication aims to contribute to the growing knowledge base in the field and pave the way for further advancements in personalized and targeted treatment approaches.
link: Click here
Source: Antonio Passaro/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023